<DOC>
	<DOCNO>NCT00718887</DOCNO>
	<brief_summary>Switching Entecavir result superior antiviral efficacy compare continue Adefovir patient suboptimal response Adefovir</brief_summary>
	<brief_title>Suboptimal Responders Adefovir Switching Entecavir</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<criteria>Chronic infection hepatitis B virus ( HBV ) ( detectable hepatitis B surface antibody ( HBsAg ) screen least 24 week prior screen , detectable HBsAg &lt; 24 week negative immunoglobulin M core antibody ) Documentation hepatitis B e antigen ( HBeAg ) positive negative status Naive nucleoside/nucleotide analogues , exception adefovir Suboptimal response adefovir treatment No lamivudine/telbivudine , entecavir , adefovir resistanceassociated substitution screen Male female gender , age 16 year older Compensated liver function Serum alanine aminotransferase level &lt; 10*upper limit normal screen Women pregnant breastfeed Evidence decompensated cirrhosis Coinfection HIV , hepatitis C virus , hepatitis D virus Recent history pancreatitis ( within 24 week prior first dose study medication ) Chronic renal insufficiency , define creatinine clearance &lt; 50 mL/min Current abuse illegal drug alcohol , sufficient investigator 's opinion prevent adequate compliance study therapy increase risk hepatotoxicity pancreatitis Other serious medical condition might preclude completion study require chronic administration prohibit medication Serum creatinine level &gt; 1.5 mg/dL ; hemoglobin level &lt; 10.0 g/dL ; platelet count &lt; 70,000/mm^3 ; absolute neutrophil count &lt; 1500 cells/mm^3 ; serum alpha fetoprotein level &gt; 100 ng/mL Except adefovir , prior therapy nucleoside nucleotide analogue antiviral agent activity hepatitis B ( eg , lamivudine , entecavir ) , experimental antiHBV antiviral , China Traditional Medicine Therapy interferon , thymosin alpha , immunostimulators within 24 week randomization Required chronic administration medication cause immunosuppression , associate high risk nephrotoxicity hepatotoxicity , affect renal excretion .</criteria>
	<gender>All</gender>
	<minimum_age>16 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>